Taken together, these data strongly support the notion that evaluation of the oncogenic mutation (BRAF vs. NRAS) together with the expression of the ER subtype (ERβ vs. ERα) in melanoma patients should be taken into consideration when considering the most specific therapeutic approach to be applied. This evidence concerns the gene ESR1 and melanoma.